OpenAI just acquired Orchestra Bio to combine agentic workflows with its Rosalind life sciences suite. The integration is designed to let AI handle coordination hiccups across complex trials and compress the grueling 10-to-15-year drug development cycle for partners like Novo Nordisk and Moderna.
OpenAI just launched the Rosalind Academic Plan, offering eligible U.S. university labs up to 30 free seats for 12 months to access GPT-Rosalind and its life-sciences workbench. Labs get specialized reasoning tools for drug discovery and genomics without their data being used for training. Why it matters: Frontier bio-AI brings huge potential alongside real biosafety concerns, so OpenAI is lowering the cost barrier for vetted academic researchers first, though API access remains excluded.
